Fulcrum Therapeutics (FULC) , a clinical-stage company, is expected to report third-quarter 2024 results early next month. The Zacks Consensus Estimate for the to-be-reported quarter's loss is pinned at 40 cents per share. The company currently does not have any marketed products and does not record any revenues. The Zacks Consensus Estimate for Fulcrum's loss per share has narrowed from 46 cents to 28 cents for 2024 over the past 60 days, while that for 2025 has narrowed from $1.51 to $1.14. FULC Estimate ...